Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
Authors
Keywords
Atherosclerosis, Low-density lipoprotein-cholesterol, PCSK9 inhibitors, Small-molecule drugs, Protein–protein interaction inhibitors
Journal
DRUG DISCOVERY TODAY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-02-02
DOI
10.1016/j.drudis.2022.01.014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sesquiterpenoids from the Aerial Parts of Salvia plebeia with Inhibitory Activities on Proprotein Convertase Subtilisin/Kexin Type 9 Expression
- (2021) Piseth Nhoek et al. JOURNAL OF NATURAL PRODUCTS
- Synthesis of Moracin C and Its Derivatives with a 2-arylbenzofuran Motif and Evaluation of Their PCSK9 Inhibitory Effects in HepG2 Cells
- (2021) Jagadeesh Nagarajappa Masagalli et al. MOLECULES
- Structure–activity relationship and biological evaluation of berberine derivatives as PCSK9 down-regulating agents
- (2021) Tian–Yun Fan et al. BIOORGANIC CHEMISTRY
- Dilignans with a Chromanol Motif Discovered by Molecular Networking from the Stem Barks of Magnolia obovata and Their Proprotein Convertase Subtilisin/Kexin Type 9 Expression Inhibitory Activity
- (2021) Jongmin Ahn et al. Biomolecules
- Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
- (2021) Brian Tomlinson et al. Endocrinology and Metabolism
- Prenylated Flavonoid Glycosides with PCSK9 mRNA Expression Inhibitory Activity from the Aerial Parts of Epimedium koreanum
- (2021) Eeray Kim et al. MOLECULES
- Identification of neolignans with PCSK9 downregulatory and LDLR upregulatory activities from Penthorum chinense and the potential in cholesterol uptake by transcriptional regulation of LDLR via SREBP2
- (2021) Hee-Sung Chae et al. JOURNAL OF ETHNOPHARMACOLOGY
- A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove
- (2020) Benny J. Evison et al. BIOORGANIC & MEDICINAL CHEMISTRY
- A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation of FoxO1/3 and HNF1α
- (2020) Xuelei Wang et al. EBioMedicine
- Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats
- (2020) Zhen-li Su et al. ACTA PHARMACOLOGICA SINICA
- Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a
- (2020) Chuan-Jue Cui et al. Journal of Translational Medicine
- From Methylene Bridged Diindole to Carbonyl Linked Benzimidazoleindole: Development of Potent and Metabolically Stable PCSK9 Modulators
- (2020) Haibo Xie et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor
- (2020) Khaldoun S. Abdelwahed et al. PHARMACOLOGICAL RESEARCH
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain and Relevance for Neuropsychiatric Disorders
- (2020) Emma M. O’Connell et al. Frontiers in Neuroscience
- Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression
- (2020) Dandan Wang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Lipid-Lowering Activities of Cucurbitacins Isolated from Trichosanthes cucumeroides and Their Synthetic Derivatives
- (2020) Xianjing Zhang et al. JOURNAL OF NATURAL PRODUCTS
- In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model
- (2019) Alba Carreras et al. BMC BIOLOGY
- Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
- (2019) Michelle L. O'Donoghue et al. CIRCULATION
- Pretreatment With PCSK9 Inhibitor Protects the Brain Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Neuronal Inflammation and Amyloid Beta Aggregation
- (2019) Nattayaporn Apaijai et al. Journal of the American Heart Association
- Prenylated Flavonoids from the Roots and Rhizomes of Sophora tonkinensis and Their Effects on the Expression of Inflammatory Mediators and Proprotein Convertase Subtilisin/Kexin Type 9
- (2019) Jongmin Ahn et al. JOURNAL OF NATURAL PRODUCTS
- Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
- (2019) Maria Pia Adorni et al. Frontiers in Aging Neuroscience
- 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9
- (2019) Hui-hui Li et al. ACTA PHARMACOLOGICA SINICA
- Discovery of 2,3′-diindolylmethanes as a novel class of PCSK9 modulators
- (2019) Gabrielle N. Winston-McPherson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Computationally Driven Structure Optimization, Synthesis, and Biological Evaluation of Imidazole-Based Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Inhibitors
- (2019) Carmen Lammi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia
- (2019) Chenglin Wu et al. Acta Pharmaceutica Sinica B
- Fragment-based design of small molecule PCSK9 inhibitors using simulated annealing of chemical potential simulations
- (2019) Frank Guarnieri et al. PLoS One
- Zebrafish-Based Discovery of Antiseizure Compounds from the Red Sea: Pseurotin A2 and Azaspirofuran A
- (2018) Daniëlle Copmans et al. ACS Chemical Neuroscience
- Small molecule modulators of PCSK9 – A literature and patent overview
- (2018) Daniel Pettersen et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Therapeutic potential of quercetin as a cardiovascular agent
- (2018) Rahul V. Patel et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Pinostrobin Inhibits Proprotein Convertase Subtilisin/Kexin-type 9 (PCSK9) Gene Expression through the Modulation of FoxO3a Protein in HepG2 Cells
- (2018) Wan-Yun Gao et al. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
- Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents
- (2018) Allyn T. Londregan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain–Fused Anticalin Protein
- (2018) Yusuke Masuda et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Small Molecule Inhibitors of the PCSK9·LDLR Interaction
- (2018) Jaru Taechalertpaisarn et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Discovery of Flavonoids from Scutellaria baicalensis with Inhibitory Activity Against PCSK 9 Expression: Isolation, Synthesis and Their Biological Evaluation
- (2018) Piseth Nhoek et al. MOLECULES
- Naringin Activates AMPK Resulting in Altered Expression of SREBPs, PCSK9, and LDLR To Reduce Body Weight in Obese C57BL/6J Mice
- (2018) Guo-Guang Sui et al. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
- Discovery of N-(piperidin-3-yl)-N-(pyridin-2-yl)piperidine/piperazine-1-carboxamides as small molecule inhibitors of PCSK9
- (2018) Allyn T. Londregan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Small molecules as inhibitors of PCSK9: Current status and future challenges
- (2018) Shengtao Xu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice
- (2017) Christine Landlinger et al. EUROPEAN HEART JOURNAL
- New Aromatic Compounds from the Fruiting Body of Sparassis crispa (Wulf.) and Their Inhibitory Activities on Proprotein Convertase Subtilisin/Kexin Type 9 mRNA Expression
- (2017) Sunghee Bang et al. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
- Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
- (2017) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2017) Mohsen Naghavi et al. LANCET
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibiting Translation One Protein at a Time
- (2017) Matthew D. Disney TRENDS IN BIOCHEMICAL SCIENCES
- Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
- (2017) Camilla Gustafsen et al. Nature Communications
- Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
- (2017) Nathanael G. Lintner et al. PLOS BIOLOGY
- A Phase I Randomized Study of a Specifically Engineered, pH-Sensitive PCSK9 Inhibitor RN317 (PF-05335810) in Hypercholesterolemic Subjects on Statin Therapy
- (2016) M Levisetti et al. CTS-Clinical and Translational Science
- Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
- (2016) John J.P. Kastelein et al. EUROPEAN HEART JOURNAL
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Disrupting the PCSK9/LDLR protein–protein interaction by an imidazole-based minimalist peptidomimetic
- (2016) Mattia Stucchi et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients
- (2016) Tong Shen et al. PHARMACEUTICAL RESEARCH
- Divergent Reactivity of Rhodium(I) Carbenes Derived from Indole Annulations
- (2015) Xiaoxun Li et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
- (2015) Maciej Banach et al. Archives of Medical Science
- Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
- (2015) Nathalie Bergeron et al. CIRCULATION
- Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor
- (2015) Rocco Romagnuolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Metabolites Produced by the Endophytic Fungus Aspergillus fumigatus from the Stem of Erythrophloeum fordii Oliv.
- (2015) Yu-Sheng Shi et al. MOLECULES
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Application of the Ugi reaction with multiple amino acid-derived components: synthesis and conformational evaluation of piperazine-based minimalist peptidomimetics
- (2015) Mattia Stucchi et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)
- (2014) Daniel Gaudet et al. AMERICAN JOURNAL OF CARDIOLOGY
- Trial evaluating evolocumab, a pcsk9 antibody, in patients with homozygous fh (tesla): Results of the randomized, double-blind, placebo-controlled trial
- (2014) F. Raal et al. ATHEROSCLEROSIS
- Copper-catalyzed tandem annulation/arylation for the synthesis of diindolylmethanes from propargylic alcohols
- (2014) Hui Li et al. CHEMICAL COMMUNICATIONS
- Design and Synthesis of Truncated EGF-A Peptides that Restore LDL-R Recycling in the Presence of PCSK9 In Vitro
- (2014) Christina I. Schroeder et al. CHEMISTRY & BIOLOGY
- PCSK9
- (2014) Nabil G. Seidah et al. CIRCULATION RESEARCH
- Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
- (2014) M. Cuchel et al. EUROPEAN HEART JOURNAL
- Aloe-emodin from rhubarb (Rheum rhabarbarum) inhibits lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages
- (2014) Boyang Hu et al. JOURNAL OF ETHNOPHARMACOLOGY
- Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
- (2014) Frederick J. Raal et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
- (2014) Gergana Galabova et al. PLoS One
- Small molecule probes that perturb a protein–protein interface in antithrombin
- (2014) Dongyue Xin et al. Chemical Science
- Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture
- (2014) Majambu Mbikay et al. FEBS Open Bio
- PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
- (2013) Emile Levy et al. ATHEROSCLEROSIS
- Immunity, atherosclerosis and cardiovascular disease
- (2013) Johan Frostegård BMC Medicine
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
- (2013) Evan A. Stein et al. CIRCULATION
- Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
- (2013) Yingnan Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Platinum-Catalyzed Tandem Indole Annulation/Arylation for the Synthesis of Diindolylmethanes and Indolo[3,2-b]carbazoles
- (2013) Dongxu Shu et al. ORGANIC LETTERS
- Synthesis and cytotoxic activity evaluation of dihydrocucurbitacin B and cucurbitacin B derivatives
- (2012) Karen Luise Lang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)
- (2012) Harshal A. Deshmukh et al. JOURNAL OF LIPID RESEARCH
- Exploring Key Orientations at Protein–Protein Interfaces with Small Molecule Probes
- (2012) Eunhwa Ko et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- The biology and therapeutic targeting of the proprotein convertases
- (2012) Nabil G. Seidah et al. NATURE REVIEWS DRUG DISCOVERY
- Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue
- (2011) Anna Roubtsova et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Triglycerides and Cardiovascular Disease
- (2011) Michael Miller et al. CIRCULATION
- Hyperlipidemia-Triggered Neutrophilia Promotes Early Atherosclerosis
- (2010) Maik Drechsler et al. CIRCULATION
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia
- (2010) Hans J. Avis et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Evaluation of the antitumoral effect of dihydrocucurbitacin-B in both in vitro and in vivo models
- (2009) Jarbas Mota Siqueira et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression
- (2009) Patrick Labonté et al. HEPATOLOGY
- A randomized, multicentre, open-label, parallel-group trial to compare the efficacy and safety profile of daming capsule in patients with hypercholesterolemia
- (2009) Ai Jing et al. PHYTOTHERAPY RESEARCH
- Molecular basis of PCSK9 function
- (2008) Gilles Lambert et al. ATHEROSCLEROSIS
- Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
- (2008) Ahmed Zaid et al. HEPATOLOGY
- Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants
- (2008) Matthew J. Bottomley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now